Gianluca Trifirò1, Fabrizio Parrino2, Valeria Pizzimenti2, Francesco Giorgianni2, Janet Sultana2, Marco Muscianisi2, Chiara Troncone3, Daniele U Tari3, Vincenzo Arcoraci2, Domenico Santoro2, Giusi Russo2, Viviana Lacava2, Achille P Caputi4. 1. Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Department of Clinical and Experimental Medicine, Policlinico Universitario G. Martino, University of Messina, Via Consolare Valeria, 98125, Messina, Italy. trifirog@unime.it. 2. Pharmacology Section, Department of Clinical and Experimental Medicine, Policlinico Universitario G. Martino, University of Messina, Via Consolare Valeria, 98125, Messina, Italy. 3. Caserta-Local Health Service, Caserta, Italy. 4. Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Department of Clinical and Experimental Medicine, Policlinico Universitario G. Martino, University of Messina, Via Consolare Valeria, 98125, Messina, Italy.
Abstract
BACKGROUND AND OBJECTIVES: Diabetes mellitus in patients with chronic kidney disease (CKD) is known as diabetic kidney disease (DKD). Pharmacological management of DKD is challenging due to reduced renal excretion of some antidiabetic drugs. The aim of this population-based study was to explore antidiabetic drug use in DKD patients from Southern Italy. METHODS: The Arianna database from Caserta Local Health Unit was used. Diabetic patients with incident CKD [first diagnosis date: index date (ID)] were identified by searching for specific ICD9-CM codes among hospital discharge diagnoses/procedures and/or indication of use associated with drug prescriptions. To evaluate any change in the use of antidiabetic drugs after the CKD diagnosis, the prevalence of antidiabetic drug use among DKD patients was calculated within 1 year prior to/after ID and after dialysis entry. A Kaplan-Meier analysis was used to assess the time to discontinuation of antidiabetic drugs after CKD diagnosis. The frequency of antidiabetic drugs contraindicated in renal disease in DKD patients was measured. RESULTS: Overall, 725 diabetic patients (mean age 72.8 ± 11.4 years) had incident CKD from 2006 to 2011. The use of combination antidiabetic drugs, biguanides and sulphonamides decreased by approximately 10, 7 and 5%, respectively, after the ID. The use of insulins increased by 10% after the ID and by 20% after entry into dialysis. The use of antidiabetic drugs not contraindicated in CKD decreased marginally after the diagnosis of CKD. CONCLUSION: In a general practice of Southern Italy the management of diabetes mellitus changed only marginally in newly diagnosed CKD patients, suggesting a therapeutic inertia on the part of prescribers.
BACKGROUND AND OBJECTIVES:Diabetes mellitus in patients with chronic kidney disease (CKD) is known as diabetic kidney disease (DKD). Pharmacological management of DKD is challenging due to reduced renal excretion of some antidiabetic drugs. The aim of this population-based study was to explore antidiabetic drug use in DKD patients from Southern Italy. METHODS: The Arianna database from Caserta Local Health Unit was used. Diabeticpatients with incident CKD [first diagnosis date: index date (ID)] were identified by searching for specific ICD9-CM codes among hospital discharge diagnoses/procedures and/or indication of use associated with drug prescriptions. To evaluate any change in the use of antidiabetic drugs after the CKD diagnosis, the prevalence of antidiabetic drug use among DKD patients was calculated within 1 year prior to/after ID and after dialysis entry. A Kaplan-Meier analysis was used to assess the time to discontinuation of antidiabetic drugs after CKD diagnosis. The frequency of antidiabetic drugs contraindicated in renal disease in DKD patients was measured. RESULTS: Overall, 725 diabeticpatients (mean age 72.8 ± 11.4 years) had incident CKD from 2006 to 2011. The use of combination antidiabetic drugs, biguanides and sulphonamides decreased by approximately 10, 7 and 5%, respectively, after the ID. The use of insulins increased by 10% after the ID and by 20% after entry into dialysis. The use of antidiabetic drugs not contraindicated in CKD decreased marginally after the diagnosis of CKD. CONCLUSION: In a general practice of Southern Italy the management of diabetes mellitus changed only marginally in newly diagnosed CKD patients, suggesting a therapeutic inertia on the part of prescribers.
Authors: Katherine Gooch; Bruce F Culleton; Braden J Manns; Jianguo Zhang; Helman Alfonso; Marcello Tonelli; Cy Frank; Scott Klarenbach; Brenda R Hemmelgarn Journal: Am J Med Date: 2007-03 Impact factor: 4.965
Authors: G Pugliese; A Solini; E Bonora; C Fondelli; E Orsi; A Nicolucci; G Penno Journal: Nutr Metab Cardiovasc Dis Date: 2014-03-01 Impact factor: 4.222
Authors: J Sultana; U M Musazzi; Y Ingrasciotta; F Giorgianni; V Ientile; A Fontana; P Minghetti; M Perrotta; D Santoro; V Savica; G Trifirò Journal: Nutr Metab Cardiovasc Dis Date: 2015-06-11 Impact factor: 4.222
Authors: Josep Franch-Nadal; Fermín García-Gollarte; Alfonso Pérez Del Molino; María L Orera-Peña; Marta Rodríguez de Miguel; Malena Melogno-Klinkas; Héctor D de Paz; Susana Aceituno; Patricia Rodríguez-Fortúnez Journal: Clin Drug Investig Date: 2019-01 Impact factor: 2.859
Authors: Johannes Pöhlmann; Roberta Montagnoli; Giusi Lastoria; Witesh Parekh; Marie Markert; Barnaby Hunt Journal: Clinicoecon Outcomes Res Date: 2019-10-07